INmune Bio Stock Target Price and Analyst Consensus
| INMB Stock | USD 9.22 0.94 9.25% |
The current analyst and expert consensus on INmune Bio is Strong Buy, with 3 strong buy opinions. The current projected INmune Bio target price consensus is 19.83 with 6 analyst opinions. Check out Macroaxis Advice on INmune Bio to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.The most common way INmune Bio analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview INmune Bio executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on INmune Bio. We strongly encourage you to use your own analysis of INmune Bio to validate this buy or sell advice. INmune Bio buy-or-sell recommendation module provides average expert sentiment on the projected INmune Bio target price to derive its highest and lowest estimates based on projected price volatility of 5.8785.
Lowest Forecast 18.05 | Highest Forecast 22.01 | Target Price 19.83 |
INmune |
It's important to approach INmune Bio's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
INmune Bio Target Price Consensus
INmune target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. INmune Bio's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most INmune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand INmune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of INmune Bio, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationINmune Bio Target Price Projection
INmune Bio's current and average target prices are 9.22 and 19.83, respectively. The current price of INmune Bio is the price at which INmune Bio is currently trading. On the other hand, INmune Bio's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On INmune Bio Target Price
INmune Bio Analyst Ratings
INmune Bio's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about INmune Bio stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of INmune Bio's financials, market performance, and future outlook by experienced professionals. INmune Bio's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize INmune Bio price targets
INmune Bio's stock target price is an estimate of its future price, usually made by analysts. Using INmune Bio's target price to determine if it is a suitable investment can be done through the following steps:- Look at INmune Bio's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if INmune Bio's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional INmune Bio Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of INmune Bio is a key component of INmune Bio valuation and have some predictive power on the future returns of a INmune Bio.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested over 90 shares | |
 | Utilities Invested over 90 shares | |
 | Apparel Invested over 90 shares | |
 | Business Services Invested over 100 shares | |
 | Banking Invested over 30 shares | |
 | Artificial Intelligence Invested few shares | |
 | Momentum Invested over 60 shares | |
 | Manufacturing Invested over 30 shares | |
 | Investor Favorites Invested over 30 shares | |
 | Warren Buffett Holdings Invested few shares | |
 | Insurance Invested over 200 shares | |
Check out Macroaxis Advice on INmune Bio to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Please note, the presentation of INmune Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, INmune Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of INmune Bio's management manipulating its earnings.